Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Shares Issued (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Shares Issued over the past 3 years, most recently at $67.0 million for Q4 2025.

  • Quarterly results put Shares Issued at $67.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $237.9 million (up 881159.26% YoY), and the annual figure for FY2025 was $237.9 million, up 881159.26%.
  • Shares Issued for Q4 2025 was $67.0 million at Tonix Pharmaceuticals Holding, down from $94.9 million in the prior quarter.
  • Over the last five years, Shares Issued for TNXP hit a ceiling of $94.9 million in Q3 2025 and a floor of $4000.0 in Q3 2024.
  • Median Shares Issued over the past 3 years was $9.7 million (2023), compared with a mean of $28.5 million.
  • Biggest five-year swings in Shares Issued: tumbled 99.96% in 2024 and later surged 2371425.0% in 2025.
  • Tonix Pharmaceuticals Holding's Shares Issued stood at $9.2 million in 2023, then plummeted by 99.96% to $4000.0 in 2024, then soared by 1673750.0% to $67.0 million in 2025.
  • The last three reported values for Shares Issued were $67.0 million (Q4 2025), $94.9 million (Q3 2025), and $13.9 million (Q2 2025) per Business Quant data.